secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001193125-24-196507
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine Q2 net loss $26.4M; cash $500.9M; positive EHA data across pipeline
--------------------------------------------------------------------------------

- Net loss of $26.4M for Q2 2024 vs $15.9M in Q2 2023; R&D expenses rose to $23.5M.
- Cash, cash equivalents & marketable securities of $500.9M as of June 30, 2024; raised $178M in June offering.
- Presented positive data for bitopertin (EPP), DISC-0974 (anemia of MF), and DISC-3405 (hepcidin) at EHA 2024.
- Expects regulatory interactions for bitopertin and DISC-0974 in H2 2024; DISC-3405 MAD data also expected in H2.
- Cash runway expected to fund operations well into 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312524196507/0001193125-24-196507-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312524196507/d802145d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-196507

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer